Literature DB >> 22640513

Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment.

D Lamunu1, K N Chapman, P Nsubuga, G Muzanyi, Y Mulumba, M A Mugerwa, S Goldberg, L Bozeman, M Engle, J Saukkonen, S Mastranunzio, H Mayanja-Kizza, J L Johnson.   

Abstract

SETTING: Clinical trials can provide a high standard of patient care and contribute to scientific knowledge; however, only a fraction of the patients screened participate and receive treatment as part of a trial.
OBJECTIVE: To explore reasons why patients were not enrolled in an international tuberculosis (TB) treatment trial and to compare experiences among study sites.
DESIGN: An analysis of reasons why patients were not enrolled was conducted among patients screened for a TB clinical trial at 26 sites in North and South America, Africa, and Europe.
RESULTS: Staff at study sites screened 1119 potential candidates for the trial: 61% (n = 686) were not enrolled due to 1) failure to meet eligibility criteria (n = 405, 59%), 2) site's decision (n = 168, 24%), or 3) candidate's choice (n = 113, 16%). Study staff recorded a total of 144 reasons for why they believed patients chose not to participate, including concerns over research (28%), conflicts with work or school (21%), and lifestyle and family issues (20%). Socio-demographic and geographic factors also influenced participation.
CONCLUSION: Increased evaluation of screening outcomes and of specific interventions, such as improved education and communication about trial procedures, may increase the efficiency of screening and enrollment in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22640513      PMCID: PMC5349184          DOI: 10.5588/ijtld.11.0434

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  14 in total

1.  What motivates lay volunteers in high burden but resource-limited tuberculosis control programmes? Perceptions from the Northern Cape province, South Africa.

Authors:  S Kironde; S Klaasen
Journal:  Int J Tuberc Lung Dis       Date:  2002-02       Impact factor: 2.373

2.  Clinical trials: the challenge of recruitment and retention of participants.

Authors:  Raisa B Gul; Parveen A Ali
Journal:  J Clin Nurs       Date:  2010-01       Impact factor: 3.036

Review 3.  Barriers to participation in randomised controlled trials: a systematic review.

Authors:  S Ross; A Grant; C Counsell; W Gillespie; I Russell; R Prescott
Journal:  J Clin Epidemiol       Date:  1999-12       Impact factor: 6.437

Review 4.  Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature.

Authors:  P M Ellis
Journal:  Ann Oncol       Date:  2000-08       Impact factor: 32.976

5.  Who refuses enrollment in cardiac clinical trials?

Authors:  Mimi Sen Biswas; L Kristin Newby; Lori A Bastian; Eric D Peterson; Jeremy Sugarman
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

6.  Reasons for participating in randomised controlled trials: conditional altruism and considerations for self.

Authors:  Sharon K McCann; Marion K Campbell; Vikki A Entwistle
Journal:  Trials       Date:  2010-03-22       Impact factor: 2.279

7.  Education level, primary language, and comprehension of the informed consent process.

Authors:  Peter E Breese; William J Burman; Stefan Goldberg; Stephen E Weis
Journal:  J Empir Res Hum Res Ethics       Date:  2007-12       Impact factor: 1.742

8.  Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

Authors:  Susan E Dorman; John L Johnson; Stefan Goldberg; Grace Muzanye; Nesri Padayatchi; Lorna Bozeman; Charles M Heilig; John Bernardo; Shurjeel Choudhri; Jacques H Grosset; Elizabeth Guy; Priya Guyadeen; Maria Corazon Leus; Gina Maltas; Dick Menzies; Eric L Nuermberger; Margarita Villarino; Andrew Vernon; Richard E Chaisson
Journal:  Am J Respir Crit Care Med       Date:  2009-04-30       Impact factor: 21.405

9.  Reasons for participation and non-participation in a randomized controlled trial: postal questionnaire surveys of women eligible for TOMBOLA (Trial Of Management of Borderline and Other Low-Grade Abnormal smears).

Authors:  L Sharp; S C Cotton; L Alexander; E Williams; N M Gray; J M Reid
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

Review 10.  Questionnaires in clinical trials: guidelines for optimal design and administration.

Authors:  Phil Edwards
Journal:  Trials       Date:  2010-01-11       Impact factor: 2.279

View more
  3 in total

1.  Participation in the SUCCESS-A Trial Improves Intensity and Quality of Care for Patients with Primary Breast Cancer.

Authors:  U Andergassen; N S Kasprowicz; P Hepp; C Schindlbeck; N Harbeck; M Kiechle; H Sommer; M W Beckmann; K Friese; W Janni; B Rack; C Scholz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-01       Impact factor: 2.915

2.  Nonparticipation reasons in a randomized international trial of a new latent tuberculosis infection regimen.

Authors:  Kimberley N Chapman Hedges; Andrey S Borisov; Jussi J Saukkonen; Nigel A Scott; Emily J Hecker; Lorna Bozeman; Carol Dukes Hamilton; Amy Kerrigan; Patricia Bessler; Antonio Moreno-Martinez; Bert Arevalo; Stefan V Goldberg
Journal:  Clin Trials       Date:  2019-11-06       Impact factor: 2.599

3.  Reasons for Non-Enrollment in Treatment among Multi-Drug Resistant Tuberculosis Patients in Hunan Province, China.

Authors:  Zuhui Xu; Tao Xiao; Yanhong Li; Kunyun Yang; Yi Tang; Liqiong Bai
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.